Develop Safe, Targeted In Vivo Delivery of RNA, Viral or Gene-Editing Payloads with Clarity in Regulations & Translational Strategy

June 03-05, 2025 | Boston, MA

2025 Agenda
Register
Become a Partner

Advance the Next Frontier of In Vivo Approaches from Research to Clinic

The in vivo approach is revolutionizing the cell and gene space. These ground-breaking technologies promise more efficient, accessible and cost-effective therapies and paving the way for the future of cell and gene treatments. With leading companies entering the clinic and investments and collaborations unfolding, the potential of in vivo therapies to treat a variety of indications including oncology, genetic and rare diseases is now front and centre.

Welcome to the 4th In Vivo Cell Engineering & Gene Editing Summit, the premier event dedicated to enhancing the next frontier of in vivo cell and gene approaches from research to clinic. This summit provides you with exclusive insights into the latest IND enabling data, regulatory and inter-governmental processes and requirements, best-in-class delivery technologies, cutting-edge innovations in editing and engineering and insights into effective clinical trial design from industry leaders including Capstan Therapeutics, Editas Medicine, Carisma Therapeutics, AbbVie, Intellia Therapeutics, Umoja BiopharmaΒ and many more!Β 

Gain exclusive access to groundbreaking discoveries and networking opportunities to propel your pipelines to new heights!Β Β 

58621 - Agenda Cover - 604x855
View the Agenda

"In vivo genetic medicines are the future, so having a forum for leaders in the field to explore ways to navigate development to meet the needs of patients is very exciting"
Nicolas Boyle, Chief Executive Officer, Abintus Bio

World-Class Speaker Faculty Includes:

CΓ©cile Bauche

Founder & Chief Scientific Officer

Alaya.bio

Adrian Bot

Founding Chief Scientific Officer & Executive Vice President - Research Development

Capstan Therapeutics

Delai Chen

Director - Nanoparticle Formulation

Beam Therapeutics Inc.

Gilmore O’Neill

President & Chief Executive Officer

Editas Medicine

Michael Klichinsky

Co-Founder & Chief Scientific Officer

Carisma Therapeutics

Laura Green

Director, Program Management

Umoja Biopharma

2025 Speaker Lineup

"The In Vivo Cell Engineering & Gene Editing Summit is a tremendous opportunity to engage with leaders in the field and discuss the latest advances"
Colin Exline, Head of Gene Editing, Primera Therapeutics

Latest Industry News

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT)

Editas Medicine Announces Strategic Transition to In Vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Nona Biosciences Partners with Alaya.bio for CAR-T Therapy

Capstan Heats Up β€˜In Vivo’ Cell Therapy Chase with $175M Fundraise

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

Download the 2025 Agenda for More Information on:

        • 20+ In Vivo Expert Speakers
        • 2 Interactive Deep-Dive Workshops
        • 8+ Hours of Industry Networking
        • & Much More!
58621 - Agenda Cover - 604x855
View the Agenda
Back to Top